However, only approximately 50% of SMOi-resistant medulloblastomas were shown to acquire mutations in the SHH pathway in a preclinical study (10), suggesting that additional mechanisms of resistance to SMOis must exist. This evidence concerns the gene SHH and medulloblastoma.